• Title/Summary/Keyword: Heart Neoplasms

Search Result 93, Processing Time 0.025 seconds

An Unusual Presentation of Schwannoma in the Interatrial Space

  • Jung, Joon Chul;Chang, Hyoung Woo;Kim, Kyung-Hwan
    • Journal of Chest Surgery
    • /
    • v.48 no.1
    • /
    • pp.95-97
    • /
    • 2015
  • We report the case of a 69-year-old woman who was diagnosed with intracardiac schwannoma without symptoms. Preoperative echocardiography and cardiac magnetic resonance imaging showed a mass attached to the interatrial septum. The initial diagnosis was a myxoma or a bronchogenic cyst. The tumor was successfully excised under cardiopulmonary bypass. However, the pathology of the excised tumor was consistent with schwannoma. We suggest that cardiovascular surgeons consider schwannoma to be a possible differential diagnosis for a mass close to the interatrial septum.

Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment

  • Koo, Taeryool;Kim, In Ah
    • Radiation Oncology Journal
    • /
    • v.34 no.1
    • /
    • pp.1-9
    • /
    • 2016
  • Overexpression of human epidermal growth factor receptor 2 (HER2) is found in about 20% of breast cancer patients. With treatment using trastuzumab, an anti-HER2 monoclonal antibody, systemic control is improved. Nonetheless, the incidence of brain metastasis does not be improved, rather seems to be increased in HER2-positive breast cancer. The mainstay treatment for brain metastases is radiotherapy. According to the number of metastatic lesions and performance status of patients, radiosurgery or whole brain radiotherapy can be performed. The concurrent use of a radiosensitizer further improves intracranial control. Due to its large molecular weight, trastuzumab has a limited ability to cross the blood-brain barrier. However, small tyrosine kinase inhibitors such as lapatinib, has been noted to be a promising agent that can be used as a radiosensitizer to affect HER2-positive breast cancer. This review will outline general management of brain metastases and will focus on preclinical findings regarding the radiosensitizing effect of small molecule HER2 targeting agents.

Periorbital cutaneous angiomyolipoma: a case report

  • Young Jun Kim;Min Hyub Choi;Ji Seon Cheon;Woo Young Choi
    • Archives of Craniofacial Surgery
    • /
    • v.24 no.2
    • /
    • pp.83-86
    • /
    • 2023
  • Angiomyolipomas are usually found in the kidneys of patients with tuberous sclerosis. They occur less frequently in organs such as the liver, the oral cavity, the nasal cavity, the heart, the large intestines, and the lungs. Angiomyolipomas of the skin are extremely rare, and cutaneous angiomyolipomas generally occur on the elbow, the ends of digits, the ear, and the glabella. Herein we present a rare case of angiomyolipoma occurring on the face-specifically, the right upper eyelid. We propose that upper eyelid angiomyolipoma is a hamartomatous, rather than neoplastic, lesion. Although angiomyolipoma in the periocular area is rare, it should be considered in the differential diagnosis of clinically benign masses. and regular follow-up is warranted.

Gastric Cancer and Non-Helicobacter pylori Microbiota (위암과 미생물총)

  • Yu Jin Kim
    • Journal of Digestive Cancer Research
    • /
    • v.12 no.1
    • /
    • pp.6-14
    • /
    • 2024
  • Gastric cancer is the 4th leading cause of death worldwide. The primary cause of gastric cancer is known to be Helicobacter pylori (H. pylori). The advancement of molecular biology has enabled the identification of microbiomes that could not be confirmed through cultivation, and it has been revealed that the microbial communities vary among normal mucosa, atrophic gastritis, intestinal metaplasia, and gastric cancer. It has also been confirmed that the composition of the microbial community differs depending on the presence or absence of H. pylori. Whether changes in the microbiome are causative factors in the carcinogenesis process is not yet clear. Experiments using animal models and in vitro studies on the role of microbes other than H. pylori in the carcinogenic process are underway, but the data is still insufficient.

A Comprehensive Analysis of 5-Year Outcomes in Patients with Cancer Admitted to Intensive Care Units

  • Hong, Yoonki;Kim, Woo Jin;Hong, Ji Young;Jeong, Yun-jeong;Park, Jinkyeong
    • Tuberculosis and Respiratory Diseases
    • /
    • v.85 no.2
    • /
    • pp.195-201
    • /
    • 2022
  • Background: The aim of this study was to evaluate the long-term (5-year) clinical outcomes of patients who received intensive care unit (ICU) treatment using Korean nationwide data. Methods: All patients aged >18 years with ICU admission according to Korean claims data from January 2008 to December 2010 were enrolled. These enrolled patients were followed up until December 2015. The primary outcome was ICU mortality. Results: Among all critically ill patients admitted to the ICU (n=323,765), patients with cancer showed higher ICU mortality (18.6%) than those without cancer (13.2%, p<0.001). However, there was no significant difference in ICU mortality at day 28 among patients without cancer (14.5%) and those with cancer (lung cancer or hematologic malignancies) (14.3%). Compared to patients without cancer, hazard ratios of those with cancer for ICU mortality at 5 years were: 1.90 (1.87-1.94) for lung cancer; 1.44 (1.43-1.46) for other solid cancers; and 3.05 (2.95-3.16) for hematologic malignancies. Conclusion: This study showed that the long-term survival rate of patients with cancer was significantly worse than that of general critically ill patients. However, short term outcomes of critically ill patients with cancer were not significantly different from those of general patients, except for those with lung cancer or hematologic malignancies.

Primary Malignant Cardiac Lymphoma in Right Atrium - A case report- (우심방에 발생한 원발성 악성 림프종의 수술적 치험 - 1예 보고 -)

  • Choi, Won-Suk;Han, Il-Yong;Jun, Hee-Jae;Lee, Yang-Haeng;Hwang, Youn-Ho;Cho, Kwang-Hyun
    • Journal of Chest Surgery
    • /
    • v.41 no.3
    • /
    • pp.369-372
    • /
    • 2008
  • A primary malignant lymphoma that originates in the heart is extremely rare. A 68-year-old male patient was admitted due to aggravated dyspnea. After echocardiography and chest computed tomography evaluation, a huge mass in the right atrium and the right ventricle was detected. We decided to perform emergency surgery due to a high risk of infarction and hemodynamic disturbance. After the near total removal of the huge mass in the right cardiac chamber, the interatrial septum and antero-lateral part of the right atrium were reconstructed by the use of a bovine pericardial patch. The final pathological diagnosis was a primary malignant lymphoma. The patient and his guardians refused chemotherapy (including radiotherapy), and the patient was discharged to his home, where the prognosis was hopeless.

Primary Left Atrial Myxofibrosarcoma -A case report- (좌심방에 발생한 악성 원발성 점액섬유성육종 -1예 보고-)

  • Yoon, Yoo-Sang;Lee, Cheol-Joo;Kang, Joon-Kyu;Kim, Hyung-Tai;Choi, Ho;Lee, Kyi-Beom
    • Journal of Chest Surgery
    • /
    • v.36 no.6
    • /
    • pp.422-426
    • /
    • 2003
  • Primary cardiac tumor has very low incidence, especially in cases of malignancy. A 29 year old male patient visited our cardiologic clinic for recent aggrevation of dyspnea on exertion and palpitation. Echocardiography showed a large tumor in the left atrium, which suggested the left atrial myxoma. Urgent open heart surgery was taken. The operative finding was fossa ovalis based a large tumor (35$\times$90$\times$50 mm) that invaded the posterior wall of LA and right superior pulmonary vein directly. The tumor was excised well by simple dissection, and the final pathologic report was malignant myxofibrosarcoma. His postoperative course was smooth and he was discharged in good health. Postoperative radiation and chemotherapy had taken with satisfactory clinical outcome.

Surgical Treatment of Cardiac Tumor (심장에 발생한 종양의 수술적 치료)

  • Jung, Tae-Eun;Han, Sung-Sae;Lee, Dong-Hyup
    • Journal of Chest Surgery
    • /
    • v.39 no.11 s.268
    • /
    • pp.810-814
    • /
    • 2006
  • Background: Tumors of the heart are uncommon. The aim of this study is to review our clinical experience and outcome of surgical treatment of cardiac neoplasm. Material and Method: From March 1990 to December 2005, 35 patients(14 males and 21 females) with mean age of 52.4 years underwent surgical treatment of cardiac neoplasm. The clinical and pathologic data were analyzed retrospectively. Surgical treatment consisted in complete resection of the tumor in all cases but 1 patient who was left ventricular fibroma received biopsy only. Result: Thirty cases were benign and five cases were malignant tumor. Benign tumors were myxoma(29 cases) and fibroma(1 case). Five malignant tumors were osteosarcoma, hepatocellular carcinoma, renal cell cancer, yolk sac tumor, and unclassified myxoid spindle cell type sarcoma. There were no operative mortality in benign cases and twenty seven cases of myxoma were followed up for 8 months to 15 years without recurrence. But four patients of malignant tumor were expired within six months after operation. Conclusion: Left atrial myxomas are most common benign neoplasm. Surgical treatment is effective for the benign cardiac tumors but prognosis is poor in patients with malignant cardiac tumors.

Successful Removal of Intravenous Leiomyomatosis with Extension into Inferior Vena Cava and Right Atrium (하대정맥, 우심실에 연장된 정맥내 평활근종증의 성공적 절제)

  • Shin Hong Ju;Song Kwang Jae;Hahm Shee Young;Kim Young Tak;Seo Joon Beom;Song Meong Gun
    • Journal of Chest Surgery
    • /
    • v.38 no.6 s.251
    • /
    • pp.441-444
    • /
    • 2005
  • Abdominal tumors that can grow through vascular lumen and spread to the right heart are rare. Intravenous leiomyomatosis is a rare tumor that originates from the uterus and spreads through the vessels. Although histologically benign, tumor extension with mechanical obstruction of the inferior vena cava, right cardiac cavities, or even the pulmonary artery, may occasionally result in fatal outcome. The best treatment is complete surgical resection of the entire tumor using cardiopulmonary bypass and total circulation arrest, We report a case of intravenous leiomyomatosis of the uterus that showed intravascular growth up to the right atrium. The patient underwent successful resection of the tumor by one-stage cardiotomy with laparotomy.

Impact of beta blockers on survival outcomes in ovarian cancer: a nationwide population-based cohort study

  • Baek, Min-Hyun;Kim, Dae-Yeon;Kim, Seon Ok;Kim, Ye-Jee;Park, Young-Han
    • Journal of Gynecologic Oncology
    • /
    • v.29 no.6
    • /
    • pp.82.1-82.13
    • /
    • 2018
  • Objective: The impact of beta blockers (BBs) on survival outcomes in ovarian cancer was investigated. Methods: By using Korean National Health Insurance Service Data, Cox proportional hazards regression was performed to analyze hazard ratios (HRs) with 95% confidence intervals (CIs) adjusting for confounding factors. Results: Among 866 eligible patients, 206 (23.8%) were BB users and 660 (76.2%) were non-users. Among the 206 BB users, 151 (73.3%) were non-selective beta blocker (NSBB) users and 105 (51.0%) were selective beta blocker (SBB) users. BB use in patients aged ${\geq}60$ years, longer duration use (${\geq}1$ year), in patients with Charlson Comorbidity Index (CCI) ${\geq}3$, and in cardiovascular disease including hypertension was associated with better survival outcome. These findings were observed in both NSBB and SBB. When duration of medication was analyzed based on number of days, NSBB (${\geq}180$ days) was associated with improved overall survival (OS) with a relatively shorter period of use compared to SBB (${\geq}720$ days). In multivariate Cox proportional hazards model, longer duration of BB medication (${\geq}1$ year) was an independent favorable prognostic factor for both OS and disease-specific survival in ovarian cancer patients. Conclusion: In our nationwide population-based cohort study, BB use was associated with better survival outcomes in ovarian cancer in cases of long term duration of use, in older patients, and in cardiovascular and/or other underlying disease (CCI ${\geq}3$).